Polymorphisms of MMP-2 gene are associated with systolic heart failure risk in han chinese

American Journal of the Medical Sciences

Volumn 337, Issue 5, 2009, Pages 344-348

  Hua, Yihong ^a   Song, Li ^a   Wu, Naqiong ^a   Lu, Xiangfeng ^a   Meng, Xianmin ^a   Gu, Dongfeng ^a   Yang, Yuejin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Association study; MMP 2; Polymorphism; Systolic heart failure

Indexed keywords

GELATINASE A;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HETEROZYGOTE; HOMOZYGOTE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC HEART FAILURE; AGED; CASE CONTROL STUDY; CHINA; ETHNOLOGY; GENETICS; HEART FAILURE; MIDDLE AGED; PHYSIOLOGY; RISK; SYSTOLE;

ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CHINA; FEMALE; HEART FAILURE; HOMOZYGOTE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SYSTOLE;

EID: 67649132722     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31818eb2a2     Document Type: Article

References (36)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:el54-e235.
2. Anselmi A, Suarez JA, Ansclmi G, et al. Primary cardiomyopathy in identical twins. Am J Cardiol 1975;35:97-102.
3. Littler WA. Twin studies in hypertrophic cardiomyopathy. Br Heart J 1972;34:1147-51.
4. Indik JH, Smith DE, Sobonya RE, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a case report of identical twins with heart failure. Pacing Clin Electrophysiol 2002;25:1387-90.
5. Morita H, Seidnian J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005;115:518-26.
6. Spinale FG. Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur Heart J 2004;25:631-3.
7. Cluetjens JPM, Verluyten MJA, Smits JFM, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995; 147:325-38.
8. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-82.
9. Kim HE, Dalai SS, Young E, et al. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 2000; 106:857-66.
10. Spinale FG, Coker ML, Thomas CV, et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998;82:482-95.
11. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-9.
12. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001;103:2303-9.
13. Noji Y, Shimizu M, Ino H, et al. Increased circulating matrix metal-loproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004;68:355-60.
14. Banfi C, Cavalca V, Veglia F, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 2005;26:481-8.
15. Tziakas DN, Chalikias GK, Papaioakeim M, et al. Comparison of levels of matrix metalloproteinase-2 and-3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 2005;96:1449-51.
16. George J, Patal S, Wexler D, et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloprotein-ase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-7.
17. Lalu MM, Pasini E, Schulze CJ, et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 2005;26:27-35.
18. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
19. Wang GY, Bergman MR, Nguyen AP, et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 2006;69:688-96.
20. Conrad CH, Brooks WW, Hayes JA, et al. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 1995;91:161-70.
21. Fatar M, Stroick M, Steffens M, et al. Single-nucleotide polymorphisms of MMP-2 gene in stroke subtypes. Cerebrovasc Dis 2008;26: 113-19.
22. Beranek M, Kolar P, Tschoplova S, et al. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelati-nase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis 2008;14:1114-21.
23. Langers AM, Sier CF, Hawinkels LJ, et al. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer 2008;98:1820-3.
24. Yu C, Zhou Y, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622-8.
25. Pannu H, Kim DH, Guo D, et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg 2006; 105:418-23.
26. Vasku A, Goldbergova M, Holla LI, et al. Two MMP-2 promoter polymorphisms (-790T/G and-735C/T) in chronic heart failure. Clin Chem Lab Med 2003;41:1299-303.
27. Mizon-Gerard F, de Groote P, Lamblin N, et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 2004;25:688-93.
28. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Spl in allele-specific transcriptional regulation. J Biol Chem 2001;276: 7549-58.
29. Harendza S, Lovett DH, Panzer U, et al. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 2003;278:20490-9.
30. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
31. Coker ML, Doscher MA, Thomas CV, et al. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999;277:H777-H787.
32. Tyagi SC, Kumar S, Glover G. Induction of tissue inhibitor and matrix metalloproteinase by serum in human heart-derived fibroblast and endomyocardial endothelial cells. J Cell Biochem 1995;58:360-71.
33. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metal-loproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
34. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-11.
35. Fernandez-Patron C, Stewart KG, Zhang Y, et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000;87:670-6.
36. Martinez A, Oh HR, Unsworth EJ, et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004;383:413-18.